Isidro Jarque

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 94 publications

Early Use of Fostamatinib in Immune Thrombocytopenia.

Early Use of Fostamatinib in Immune Thrombocytopenia.

Journal: Advances in therapy
Published: June 02, 2026

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Journal: American journal of hematology
Published: February 05, 2026

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

Journal: Leukemia & lymphoma
Published: August 20, 2025

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Journal: Nature cancer
Published: April 16, 2025

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Journal: Nature cancer
Published: August 14, 2024

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Journal: Annals of hematology
Published: July 24, 2024

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques.

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques.

Journal: Blood vessels, thrombosis & hemostasis
Published: May 20, 2024

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus.

Journal: Platelets
Published: May 14, 2024

Editorial: Infectious diseases and hematology: diagnosis and management.

Editorial: Infectious diseases and hematology: diagnosis and management.

Journal: Frontiers in medicine
Published: February 13, 2024

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.

Journal: Blood
Published: February 08, 2024

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Journal: Haematologica
Published: August 25, 2023

A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study).

A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study).

Journal: Annals of hematology
Published: June 22, 2023
Showing 1-12 of 94

Last Updated: 09/26/2026